The Biomarkers, Symptoms, and Treatment of Multiple Sclerosis

Guest Editor:

Dr. Clara Grazia Chisari
Department of Systems Medicine,
Università degli Studi di Roma
"Tor Vergata", Rome, Italy

Deadline for manuscript submissions:
30 November 2024

Message from the Guest Editor

Multiple sclerosis (MS) is a persistent autoimmune neurodegenerative condition. Assessing relapse rates, disability progression, and lesion load via MRI helps identify disease activity and treatment responses. However, the utilization of clinical and imaging biomarkers falls short of enabling individual characterization and prediction. Thus, blood and cerebrospinal fluid (CSF) biomarkers related to axonal and neuronal damage, glial dysfunction, demyelination, and inflammation have been explored as actionable indicators for MS, shedding light on this disease's underlying pathology.

The current Special Issue aims to provide more insights into the use of several clinical, imaging, and molecular biomarkers for the diagnosis, prognosis, and treatment response in MS, including the validation of current MS biomarkers, the application of more advanced screening technologies (e.g., gene expression and autoantibody arrays, microRNAs, and circulating microvesicles/exosomes), and the discovery of potential molecular biomarkers derived from blood or CSF samples for monitoring the impact of MS treatment in a clinical setting.

Special Issue

Editor-in-Chief

Prof. Dr. Stephen D. Meriney
Department of Neuroscience,
University of Pittsburgh,
Pittsburgh, PA 15260, USA

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Brain Sciences* (ISSN 2076-3425). *Brain Sciences* is an open access, peer-reviewed scientific journal that publishes original articles, critical reviews, research notes, and short communications on neuroscience. The scientific community and the general public can access the content free of charge as soon as it is published.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, PSYNDEX, CAPlus / SciFinder, and other databases.
Rapid Publication: manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the second half of 2023).

Contact Us